The Claim
The cardiovascular benefit of statins is entirely mediated by their reduction of LDL cholesterol, and thus, the selection of cholesterol-lowering therapy should be determined by the efficacy of LDL-C reduction, safety, cost, and tolerability, not by unverified pleiotropic effects.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Statins improve heart health solely by lowering LDL cholesterol, so choosing a cholesterol-lowering drug should depend on how well it reduces LDL cholesterol, its safety, cost, and how well it is tolerated, not on unproven additional effects.
See the scientific wording
The cardiovascular benefit of statins is fully explained by their LDL-C-lowering effect, and therefore, the choice of cholesterol-lowering therapy should be guided by LDL-C reduction efficacy, safety, cost, and tolerability rather than by assumed pleiotropic properties.
Lowering LDL cholesterol reduces the amount of fat that builds up inside artery walls, which stops new plaques from forming and makes existing plaques less likely to rupture and cause heart attacks or strokes.
What the research says
1 studyStudy: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
This study found that lowering bad cholesterol by 1% reduces heart disease risk by 1%, no matter if you use statins, diet, or surgery. So statins don’t have special extra benefits—just lowering cholesterol is what matters.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.